MDMA与MDMA辅助治疗
MDMA(3,4-亚甲二氧基甲基苯丙胺)自20世纪70年代起用于娱乐和治疗场景。FDA于2017年将MDMA辅助治疗(MDMA-AT)指定为创伤后应激障碍(PTSD)的突破性疗法,2024年拒绝初始新药申请后要求追加一项3期试验。本综述区分非临床娱乐性使用与受控临床环境下药用级MDMA辅助治疗的证据,并描述其神经生物学机制、临床证据及公共政策考量。
要点
- MDMA-AT疗程含三次MDMA给药并辅以心理治疗,PTSD患者67%-71%不再符合诊断标准,安慰剂辅助治疗为32%-48%。
- MDMA独特诱导亲社会主观效应,增强信任与自我关怀,同时保持自我功能及认知与知觉清晰。
- 娱乐性使用研究的结论受诸多混杂因素限制,难以外推至治疗性使用。
核心结论
- 大量初步证据提示,在受控临床环境中实施的MDMA-AT是治疗PTSD安全且有效的方法。
- 娱乐性使用研究的结论受诸多混杂因素限制,尤其限制了将娱乐性使用证据外推至治疗性使用的程度。
研究设计与样本
- 本综述主要旨在区分非临床环境中娱乐性使用的证据与受控临床环境中使用药用级MDMA的MDMA-AT证据。
- 综述进一步描述MDMA治疗效应背后的推定神经生物学机制、MDMA-AT的临床证据、公共卫生与政策层面的考量以及未来研究方向。
主要发现
- 经历含三次MDMA给药并辅以心理治疗的MDMA-AT疗程后,67%-71%的PTSD患者不再符合诊断标准,而安慰剂辅助治疗为32%-48%。
- MDMA-AT的效应在长期随访中持续存在。
- 与非医疗环境中的娱乐性使用不同,MDMA独特地诱导信任增强与自我关怀的亲社会主观效应,同时保持自我功能以及认知与知觉清晰。
- 非医疗环境中的娱乐性使用仍可能造成伤害,尤其因掺假物或未采取适当预防措施时。
关键数值与推荐
- FDA于2017年将MDMA-AT指定为PTSD的突破性疗法。
- FDA于2024年拒绝初始新药申请后,要求追加一项3期试验。
- MDMA-AT疗程包含三次MDMA给药并辅以心理治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 娱乐性使用研究的结论受诸多混杂因素限制。
- 娱乐性使用证据外推至治疗性使用的程度尤其受限。
- FDA于2024年拒绝初始新药申请后要求追加一项3期试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Unlike other psychedelics, MDMA uniquely induces prosocial subjective effects of heightened trust and self-compassion while maintaining ego functioning as well as cognitive and perceptual lucidity. While recreational use in nonmedical settings may still cause harm, especially due to adulterants or when used without proper precautions, conclusions that can be drawn from studies of recreational use are limited by many confounds. This especially limits the extent to which evidence related to recreational use can be extrapolated to therapeutic use. A considerable body of preliminary evidence suggests that MDMA-AT delivered in a controlled clinical setting is a safe and efficacious treatment for PTSD. After a course of MDMA-AT involving three MDMA administrations supported by psychotherapy, 67%-71% of individuals with PTSD no longer meet diagnostic criteria after MDMA-AT versus 32%-48% with placebo-assisted therapy, and effects endure at long-term follow-up. This review primarily aims to distinguish evidence of recreational use in nonclinical settings versus MDMA-AT using pharmaceutical-grade MDMA in controlled clinical settings. This review further describes the putative neurobiological mechanisms of MDMA underlying its therapeutic effects, the clinical evidence of MDMA-AT, considerations at the level of public health and policy, and future research directions.
引用
- Wolfgang AS, Fonzo GA, Gray JC, et al. MDMA and MDMA-Assisted Therapy. Am J Psychiatry. 2025. PMID: 39741438. doi:10.1176/appi.ajp.20230681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。